Over the past two decades, the arsenal of disease-modifying therapies for multiple sclerosis (MS) has expanded considerably. This applies in particular to the relapsing-remitting form (RRMS), but the treatment options for the other subtypes have also improved. The evidence base for what is currently the only immunomodulatory therapy for primary chronic progressive MS (PPMS) has recently been expanded by several new studies.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- IMCAS Refresher: Aging Sciences/Plastic Surgery
Trends in aesthetic and regenerative medicine
- Pelargonium sidoides
Scoping review sheds light on the multifaceted spectrum of effects
- New evidence on genetics, pathophysiology and clinical significance
Migraine with and without aura – two different entities?
- Prevention of skin cancer
UV protection and skin cancer screening – Update 2025
- Case report: L. pneumophila pneumonia
Negative test results – but no alternative diagnoses
- Clinical case reports and implications for GP care
Magnesium deficiency and dilated cardiomyopathy in the peripartum context
- SID Annual Meeting: Highlights
Update on inflammatory dermatoses – a concentrated load of innovative power
- Case series